Locoregional Management of Breast Cancer Following Neoadjuvant Chemotherapy.

Purpose of Review: The treatment of breast cancer is evolving at accelerated rates. As systemic therapy continues to improve, the roles of surgery and radiation are being re-considered. The intent of this review is to discuss recent studies and potential future directions for the locoregional management of breast cancer following neoadjuvant chemotherapy. Recent Findings: For patients treated with neoadjuvant chemotherapy, treatment decisions hinge on the tumor's biomarkers and patient's response to systemic therapy. For patients who sustain a pCR, clinical trials are investigating the role of de-escalated surgery and radiation. For patients with residual disease, escalated systemic therapies have been found to be of benefit. Surgery and radiation remain a mainstay of treatment. Summary: As the indications for neoadjuvant chemotherapy expand, locoregional management continues to develop and therapy is being increasingly tailored to an individual's particular response. Practitioners must know when therapy can be safely de-escalated and indications for escalation. [ABSTRACT FROM AUTHOR]